This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Bacterial Infections  • Tuberculosis/ Other Mycobacterium  • Drug Therapy  • Adverse Effects  • Hematology/ Hematologic Malignancies  • Leukemias/ Lymphomas  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Laurence Senn, MD; Tibor Kovacsovics, MD; Philip E. Tarr, MD; Pascal Meylan, MD

Arch Intern Med. 2009;169(3):312-313.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Imatinib mesylate, a selective inhibitor of the BCR-ABL tyrosine kinase gene, is now a standard therapy in patients with chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST). Recent studies have shown that imatinib alters T-cell–mediated immune responses,^1-4 raising the possibility of opportunistic infections associated with imatinib therapy. So far, few epidemiological data are available to support this hypothesis. We report herein a case of peritoneal tuberculosis (TB) following 4 months of imatinib therapy for CML.

Report of a Case

A 37-year-old Swiss-born man was diagnosed as having BCR-ABL–positive CML, and imatinib mesylate therapy was initiated (400 mg/d). One month later, the imatinib dosage was reduced owing to an elevation in transaminase (3 times the upper limit of normal) and alkaline phosphatase (4 times the upper limit of normal) levels. Serologic test results for human immunodeficiency virus and hepatitis A, . . . [Full Text of this Article]

Comment

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?